Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 4/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 2/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12886256 | 0.82 | FFAR4 (0.40) | FFAR4CYP4F2CYP4A11CETPMRGPRX4 | |
| SCHEMBL17703932 | 0.81 | FFAR4 (0.39) | FFAR4CYP4F2CYP4A11CETPMRGPRX4 | |
| SCHEMBL16616039 | 0.81 | CYP4F2 (0.54) | FFAR4CYP4F2CYP4A11CETPMRGPRX4 | |
| SCHEMBL22090574 | 0.81 | CETP (0.35) | FFAR4CETPGPR3IDO1CHRM2 | |
| SCHEMBL16234319 | 0.81 | FFAR4 (0.39) | FFAR4CYP4F2CYP4A11CETPMRGPRX4 | |
| SCHEMBL18549862 | 0.79 | GRIN2B (0.42) | FFAR4CETPGPR3CHRM2CHRM1 | |
| SCHEMBL4065175 | 0.79 | GRIN2B (0.43) | FFAR4CETPHCRTR1HCRTR2 | |
| SCHEMBL8149838 | 0.79 | GPR3 (0.42) | FFAR4GPR3PPARAIDO1 | |
| SCHEMBL24180144 | 0.78 | FFAR4 (0.38) | FFAR4CYP4F2CYP4A11MRGPRX4GPR3 | |
| SCHEMBL22390580 | 0.78 | FFAR4 (0.38) | FFAR4CYP4F2CYP4A11CETPMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2021-07-22 | — | — | US | disclosed |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2021-05-04 | — | — | US | disclosed |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2020-09-10 | — | — | US | disclosed |
| EP-3377491-B1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2019-11-13 | — | — | EP | disclosed |
| EP-3377491-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-03-12 | — | — | US | disclosed |
| EP-2820005-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013128378-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2013-09-06 | — | — | WO | disclosed |
| EP-0075146-B1 | BENZYL ESTERS WITH FLUOROSUBSTITUTED ETHER GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR UTILISATION AS INSECTICIDES | BAYER AG (DE) | 1985-10-23 | — | — | EP | disclosed |
| EP-0075146-A1 | Benzyl esters with fluorosubstituted ether groups, process for their preparation and their utilisation as insecticides | BAYER AG (DE) | 1983-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | FFAR4 2520/4885CYP4F2 614/4885CYP4A11 470/4885 |
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | GPR55, GPR65, GPR35 | FFAR4 19/4885CYP4F2 1128/4885CYP4A11 103/4885 |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | FFAR4 3291/4885CYP4F2 528/4885CYP4A11 587/4885 |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | FFAR4 3291/4885CYP4F2 528/4885CYP4A11 587/4885 |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | FFAR4 2520/4885CYP4F2 614/4885CYP4A11 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.